Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04095936
Other study ID # 531-004
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received
Last updated
Start date December 3, 2019
Est. completion date October 29, 2021

Study information

Verified date May 2022
Source Kyowa Kirin Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the hematological responses based on the response assessment criteria defined in this study (the 531-004 response assessment criteria) when AMG531 is subcutaneously (SC)-administered with ciclosporin A (CsA) therapy for 6 months in patients with aplastic anemia (AA) who were previously untreated with immunosuppressive therapy.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date October 29, 2021
Est. primary completion date October 7, 2021
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: 1. Voluntary signed informed consent to participate in the study; 2. A diagnosis of AA confirmed by blood and bone-marrow examinations, etc.; 3. Considered to require new treatment with immunosuppressive therapy provided that NSAA must be platelet or erythrocyte transfusion-dependent. 4. An Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 to 1at screening; Exclusion Criteria: 1. Previously treated with Anti-human thymocyte immunoglobulin (ATG), CsA, or Alemtuzumab; 2. Diagnosed as having congenital AA (Fanconi anemia, congenital dyskeratosis, etc.); 3. Diagnosed as having acute myelocytic leukemia (AML) or chronic myelomonocytic leukemia; 4. Concurrent thrombocytopenia of other etiologies (e.g., myelodysplastic syndrome (MDS), idiopathic thrombocytopenic purpura (ITP), cirrhosis); 5. Concurrent active infection not adequately responding to appropriate therapy; 6. Concurrent clinically significant illness(es) items which are deemed by the Investigator to be likely to affect the study conduct and assessments. 7. Having active malignancies, or having a history of treatment of malignancies within 5 years prior to informed consent. 8. Concurrent paroxysmal nocturnal hemoglobinuria (PNH) 9. Having Grade 2 or higher bone marrow reticulin based on Bone Marrow Pathology (2nd edition) ; 10. History of chromosome aberrations discovered in bone marrow cells. 11. Having blast cells > 2% in bone marrow; 12. Positive for anti-human immunodeficiency virus (HIV) antibody; 13. Receiving prophylactic or therapeutic treatment for hepatitis type B 14. Having hepatitis C virus (HCV) infection confirmed by HCV-RNA or other tests at screening. 15. Planned hematopoietic stem cell transplantation during the study; 16. Systemic treatment with any of the following medication for the treatment of AA within 4 weeks before Day 1: - Anabolic steroids - Corticosteroids; 17. Pregnant or breastfeeding women, or women willing to become pregnant; 18. Other conditions unsuitable for participation in the study in the opinion of the Investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Romiplostim
Subcutaneous administration of 0 to 20ug/kg for 6 months

Locations

Country Name City State
Japan NTT Medical center Tokyo Shinagawa Tokyo

Sponsors (1)

Lead Sponsor Collaborator
Kyowa Kirin Co., Ltd.

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of achievement of complete response (CR) or partial response (PR) 27 weeks post-dose
Secondary Rate of achievement of CR or PR 14 weeks
Secondary Rate of achievement of CR Weeks 14 and 27
Secondary The time to CR or PR Each time point evaluated weekly until Week 27
Secondary Reduction or independence of platelet and/or erythrocyte transfusion Week 27
Secondary Change from baseline in platelet count (/µL) Each time point evaluated weekly until Week 27
Secondary Change from baseline in hemoglobin (Hb) concentration (g/dL) Each time point evaluated weekly until Week 27
Secondary Change from baseline in neutrophil count (/µL) Each time point evaluated weekly until Week 27
Secondary Change from baseline in reticulocyte count (/µL) Each time point evaluated weekly until Week 27
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03025698 - A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia Phase 2
Completed NCT00987480 - Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine Phase 2
Completed NCT00767650 - Neuropsychological Effects of Immunosuppressive Treatment in Subjects With Aplastic Anemia N/A
Not yet recruiting NCT02833493 - Study of MRI Monitoring in Patients With Aplastic Anemia and Low or Int-1 Risk of MDS Complicated With Iron Overload N/A
Completed NCT02833805 - NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia Phase 2
Recruiting NCT02028416 - Comparison of Two Different Doses of Rabbit ATG-Fresenius With Cyclosporin in the Treatment of Acquired Aplastic Anaemia N/A
Completed NCT00004474 - Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia Phase 3
Recruiting NCT05031897 - Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant Phase 2
Completed NCT04439006 - Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization Phase 1
Not yet recruiting NCT05996393 - CsA+ATG+AVA vs. CsA+AVA for the Treatment of Newly-diagnosed SAA in the Elderly Phase 4
Completed NCT02462252 - Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome Phase 2
Completed NCT01272817 - Nonmyeloablative Allogeneic Transplant N/A
Completed NCT00513175 - Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia N/A
Completed NCT00001398 - Stem Cell Factor Medication for Aplastic Anemia Phase 1
Recruiting NCT01861093 - Safety Study of Cord Blood Units for Stem Cell Transplants Phase 2
Not yet recruiting NCT05018936 - Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia Phase 2/Phase 3
Completed NCT00065260 - Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia Phase 2
Recruiting NCT02007811 - Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination Phase 1/Phase 2
Recruiting NCT01758042 - Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders N/A
Terminated NCT01500161 - Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match Phase 2